Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28566732 | 0.81 | VCAM1 (0.42) | VCAM1AREGLN2CYP11B2FLT1 | |
| SCHEMBL11938978 | 0.78 | CA12 (0.39) | ARSLC6A4CA2MAOAABCB11 | |
| SCHEMBL11554956 | 0.78 | KIF11 (0.34) | KCNH2SLC6A4EGLN2CYP11B2CYP11B1 | |
| SCHEMBL7122086 | 0.78 | ALDH1A1 (0.39) | ARSLC6A4EGLN2CYP11B2CYP11B1 | |
| SCHEMBL1021797 | 0.76 | ITGB3 (0.43) | SLC6A4MAOAABCB11ALDH1A1NR3C1 | |
| SCHEMBL29668125 | 0.76 | ITGB3 (0.43) | SLC6A4MAOAABCB11ALDH1A1NR3C1 | |
| SCHEMBL7112459 | 0.75 | GABRA1 (0.44) | ARKCNH2SLC6A4HTR2AEGLN2 | |
| SCHEMBL17289576 | 0.75 | TDP1 (0.44) | SLC6A4CA1CA2MAOAABCB11 | |
| SCHEMBL4009416 | 0.75 | GABRA1 (0.34) | VCAM1AR | |
| SCHEMBL11879096 | 0.74 | HTR3E (0.50) | VCAM1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115835866-B | Cereblon binding compounds, compositions thereof, and methods for their use in therapy | 新基公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-117715903-A | Cereblon binding compounds, compositions thereof, and methods for their use in therapy | 新基公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117561249-A | Cereblon binding compounds, compositions thereof, and methods for their use in therapy | 细胞基因公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-115968293-A | Cereblon binding compounds, compositions thereof, and methods of use thereof for treatment | 新基公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115955979-A | Cereblan binding compounds, compositions thereof, and methods for treatment thereof | 新基公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115835866-A | Cereblon binding compounds, compositions thereof, and methods of use thereof for treatment | 新基公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3822274-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-2475647-B1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | SUZHOU KINTOR PHARMACEUTICALS INC (CN) | 2015-11-04 | — | — | EP | disclosed |
| US-20140315957-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2014-10-23 | — | — | US | disclosed |
| US-8809550-B2 | Androgen receptor antagonists and uses thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2014-08-19 | — | — | US | disclosed |
| US-20120172406-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | Tong, Youzhi (CN) | 2012-07-05 | — | — | US | disclosed |
| WO-2011029392-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | TONG YOUZHI (CN) | 2011-03-17 | — | — | WO | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| CN-1337955-A | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents | AMERICAN BAYER CORP (US) | 2002-02-27 | — | — | CN | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172406-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | AR, SHBG, MUSK | VCAM1 4553/4885AR 1/4885KCNH2 3983/4885 |
| US-20230158035-A1 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, TYMP | VCAM1 4323/4885AR 2986/4885KCNH2 4535/4885 |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | VCAM1 1409/4885AR 23/4885KCNH2 3584/4885 |
| US-11590139-B2 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | TPMT, MGMT, TYMP | VCAM1 4323/4885AR 2986/4885KCNH2 4535/4885 |
| US-20140315957-A1 | ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF | AR, SHBG, MUSK | VCAM1 4553/4885AR 1/4885KCNH2 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.